

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	: Pastor <i>et al.</i>	Customer No.	: 21003
Serial No.	: 10/647,739	Confirmation No.	: 4202
Filed	: August 25, 2003	Group Art Unit	: 1614
Examiner	: Anderson, James D.		
For	: THERAPY WITH CANNABINOID COMPOUNDS FOR THE TREATMENT OF BRAIN TUMORS		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicants bring to the attention of the Examiner the documents listed on the attached Form PTO 1449 and respectfully request that the listed documents be considered by the Examiner and made of record in the above-captioned application.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute “prior art.” If the Examiner applies the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute “prior art” under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of the documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

Applicants have enclosed the required fee due in connection with this submission. If any additional fee is due, or if any overpayment has been made, the Commissioner is authorized to charge any such fee or credit any overpayment, to Deposit Account No. 02-4377.

Respectfully submitted,

BAKER BOTTS L.L.P.

August 8, 2007
Date


Sandra S. Lee
Patent Office Reg. No. 51,932

Lisa B. Kole
Patent Office Reg. No. 35,225

30 Rockefeller Plaza
44th Floor
New York, NY 10012-4498
Attorneys for Applicant(s)
212-408-2500

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/647,739
	Filing Date	08/25/2003
	Inventor(s)	Pastor <i>et al.</i>
	Art Unit	1614
	Examiner Name	James D. Anderson
	Attorney Docket Number	069277.0113

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	1.	Shinkai et al., "RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement," <i>Cell</i> . 1992 Mar 6;68(5):855-67
	2.	Grinspoon et al., "Marihuana as medicine. A plea for reconsideration," <i>JAMA</i> . 1995 Jun 21;273(23):1875-6
	3.	Skaper et al., "The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons," <i>Proc Natl Acad Sci U S A</i> . 1996 Apr 30;93(9):3984-9
	4.	Voth et al., "Medicinal applications of delta-9-tetrahydrocannabinol and marijuana," <i>Ann Intern Med</i> . 1997 May 15;126(10):791-8
	5.	Barth, "Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas," <i>J Neurooncol</i> . 1998 Jan;36(1):91-102
	6.	Childers et al., "Cannabis and endogenous cannabinoid systems," <i>Drug Alcohol Depend</i> . 1998 Jun-Jul;51(1-2):173-87
	7.	De Petrocellis et al., "The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation," <i>Proc Natl Acad Sci U S A</i> . 1998 Jul 7;95(14):8375-80
	8.	Hampson et al., "Cannabidiol and (-)-Delta9-tetrahydrocannabinol are neuroprotective antioxidants," <i>Proc Natl Acad Sci U S A</i> . 1998 Jul 7;95(14):8268-73
	9.	Shen et al., "Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity," <i>Mol Pharmacol</i> . 1998 Sep;54(3):459-62
	10.	Sanchez et al., "Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells," <i>FEBS Lett</i> . 1998 Sep 25;436(1):6-10

Examiner Signature	Date Considered
--------------------	-----------------

NY02-592973.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/647,739
	Filing Date	08/25/2003
	Inventor(s)	Pastor <i>et al.</i>
	Art Unit	1614
	Examiner Name	James D. Anderson
	Attorney Docket Number	069277.0113

11.	Shire et al., "Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528," Life Sci. 1999;65(6-7):627-35
12.	Nagayama et al., "Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures," J Neurosci. 1999 Apr 15;19(8):2987-95.
13.	Maher et al., "Malignant glioma: genetics and biology of a grave matter," Genes Dev. 2001 Jun 1;15(11):1311-33
14.	Pertwee, "International Union of Pharmacology. XXVII. Classification of cannabinoid receptors," Pharmacol Rev. 2002 Jun;54(2):161-202
15.	Casanova et al., "Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors,," J Clin Invest. 2003 Jan;111(1):43-50
16.	Castro et al., "Current and future strategies for the treatment of malignant brain tumors," Pharmacol Ther. 2003 Apr;98(1):71-108
17.	King et al., "Gene therapy and targeted toxins for glioma," Curr Gene Ther. 2005 Dec;5(6):535-57
18.	Reardon et al., "Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents," Oncologist. 2006 Feb;11(2):152-64
19.	Howlett et al., "Protective medical legislation deficient knowledge of maternity (health and safety) rights for work-adjustment exists amongst flexible trainee doctors: is there a risk to maternal and foetal health?," Eur J Obstet Gynecol Reprod Biol. 2006 Jul;127(1):79-87. Epub 2005 Nov 2.
20.	Blazquez et al., "Cannabinoid receptors as novel targets for the treatment of melanoma," FASEB J. 2006 Dec;20(14):2633-5. Epub 2006 Oct 25

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

NY02:592973.1

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.